DOS 2017

DOS Kongressen 2017 ·

155

Statin treatment is not associated with the postop-

erative risk of cardiovascular events or death after

total hip arthroplasty surgery. A population-based

study from the Danish Hip Arthroplasty Register.

Alexander Dastrup, Anton Pottegård, Søren Overgaard, Jesper Hallas

Department of Orthopaedic Surgery, Odense University Hospital; Clinical Phar-

macology and Pharmacy, University of Southern Denmark; Department of Or-

thopaedic Surgery, Odense University Hospital; Clinical Pharmacology and Phar-

macy, University of Southern Denmark

Background:

Statins may reduce the risk of postsurgical cardiovascular compli-

cations following non-vascular surgery.

Purpose / Aim of Study:

To determine whether short-term preoperative

statin treatment was associated with a reduced risk of cardiovascular events

after total hip arthroplasty (THA).

Materials and Methods:

Using the Danish Hip Arthroplasty Register, the Dan-

ish National Patient Register and the Danish National Database of Prescriptions

we included 60073 primary THA patients without a history of statin use. Of

these 2227 were prescribed statins during the 365 days before their primary

THA. 1:4 Propensity score matching new users to non- users of statins on age,

gender, year of surgery, known risk factors for cardiovascular disease, the Elix-

hauser Comorbidity Index and income resulted in a final cohort of 1674 and

6696 individuals. The primary outcome was venous thromboembolism (VTE).

Secondary outcomes were deep venous thrombosis (DVT), pulmonary embo-

lism (PE), myocardial infarction (MI), ischemic stroke and all-cause mortality.

Cox regression survival analysis was used to calculate hazard ratios (HR) and

95% confidence intervals (CI).

Findings / Results:

We found no statistically significant effect on VTE (HR =

1.0; 95% CI, 0.50-1.9), DVT (HR = 1.1; 95% CI, 0.6-2.3), PE (HR = 0.7; 95%

CI, 0.1-3.0), MI (HR = 1.2; 95% CI, 0.5-3.0), ischemic stroke (HR = 1.0; 95%

CI, 0.2-4.7) or all-cause mortality (HR = 0.3; 95% CI, 0.1-1.1).

Conclusions:

Short term statin use before primary THA is not associated with

a reduced risk of VTE, DVT, PE, ischemic stroke, MI or death from all causes.

No conflicts of interest reported

107.